The City University of New York (CUNY), New York, NY, and Soterix Medical, Inc., New York, NY, have released an image-guided neuromodulation device. The EEG-Guided High-Definition tES (HD-tES) targets brain regions associated with neuropsychiatric disorders such as depression and chronic pain.

HD-tES, a technology developed by Dr. Marom Bikson and Dr. Lucas Parra at CUNY, delivers targeted, low-intensity electrotherapy non-invasively. By embedding electrodes within a removable cap, the proprietary EEG-Guided HD-tES combines research-grade brain monitoring with clinical-grade brain stimulation.

According to the CUNY researchers, a low-intensity targeted electrical current is known to promote the brain's plasticity, or ability to change with learning. Brain plasticity is considered by some as a basis for facilitating lasting clinical benefit.

The system detects brain activity, diagnoses the brain target, and delivers mild electrotherapy (HD-tES) to the region. Research-grade EEG ensures reliable identification of brain targets while clinical-grade HD-tES supports reliable brain modulation. The number of EEG and HD-tES channels can be scaled up to 64.

"This will improve patient care in a tangible way for a variety of patient populations by providing personalized electroceutical therapy," said Doug Adams, Director of Commercialization at CUNY.

Source 


Medical Design Briefs Magazine

This article first appeared in the February, 2017 issue of Medical Design Briefs Magazine.

Read more articles from this issue here.

Read more articles from the archives here.